2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2503

Improved Pneumococcal Vaccination in Rheumatoid Arthritis Patients in an Urban Academic Rheumatology Clinic
Abstract Number: 1084

Improved Survival in Granulomatosis with Polyangiitis: A General Population-Based Study
Abstract Number: 877

Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study
Abstract Number: 3240

Improved Survival in Rheumatoid Arthritis: A General Population-Based Study
Abstract Number: 985

Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 1768

Improved Tissue Clearing and 2-Photon Imaging of Mouse Kidneys Reveals Immune Cell Architecture in Nephrotoxic Nephritis
Abstract Number: 561

Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2292

Improvement in Function and Pain Due to Subacromial Bursitis As Related to Dose of Triamcinolone Acetonide or Methylprednisolone Acetate
Abstract Number: 1014

Improvement in Mentoring Associated with Implementation of an Inter-Institutional Mentoring Program within Pediatric Rheumatology
Abstract Number: 1999

Improvement in Mortality in RA Compared to the General Population – Closing the Mortality Gap
Abstract Number: 2340

Improvement in Treat to Target Serum Urate Levels: Preliminary Results from a Comparison Between Two Audits of Management
Abstract Number: 1276

Improvement in Work and Household Productivity for Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with Anti-TNFs in Routine Clinical Practice in Turkey
Abstract Number: 2493

Improvement of Disease Activity and Quality of Care in a Cohort of Rheumatoid Arthritis Patients Treated with Conventional Dmard Therapy Under Treat to Target Recommendations and a Model of Patient-Centered Care
Abstract Number: 1476

Improvement of the Long-Term Outcome in Greek Adult Patients with Juvenile Idiopathic Arthritis in the 21st Century
Abstract Number: 1786

Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].